< back to News

Milan hosted the first Investigator Meeting of the European IMPACT-AML project, within the frame of the European Hematology Association [EHA] Congress: an opportunity to present the project’s state of the art to scientific stakeholders and launch a strong appeal to the European scientific community.

The IMPACT-AML project brings together 17 partners from across Europe, and this international collaboration is key to combining diverse expertise and driving progress in the fight against Relapsed/Refractory Acute Myeloid Leukemia. With its consortium of 17 partners across Europe, the IMPACT-AML project builds a pioneering research framework for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), unifying patients, clinicians, and researchers across Europe and beyond.

During the meeting in Milan, representatives of the experimental centers and international partners discussed the biological and clinical complexity of the disease.

“The Investigator Meeting made it clear that rapid, evidence-based responses are needed. IMPACT-AML aims precisely to create a system and find shared solutions for the currently available therapeutic options,” stated Professor Giovanni Martinelli, Associate Professor at the University of Bologna and scientific coordinator of the European IMPACT-AML project.

Another central theme of the meeting is the study design: a Randomised Pragmatic Clinical Trial (RPTC), the first of its kind for this pathology. The IMPACT-AML RPCT is a phase III, randomized, pragmatic, multicenter clinical study designed to compare low-intensity versus high-intensity treatments in adult patients with R/R AML who have received one or two prior lines of therapy.

“This study is an act of responsibility towards the patients we see every day in our hospitals. It is for them that we are building a scientific, independent and ethically solid, European network. To achieve a real impact in their lives, it is essential to expand the network, activate new centers, and involve physicians and young researchers,” added Dr. Oriana Nanni, Director of the Biostatistics and Clinical Trials Unit at IRST “Dino Amadori” IRCCS in Meldola, which coordinates the IMPACT-AML project.

One of the main elements of the project is represented by the STREAM platform, an innovative patient registry designed to transform the treatment landscape for Relapsed or Refractory Acute Myeloid Leukemia (R/R AML). By integrating patients across Europe, STREAM will ensure an inclusive, real-world registry that collects clinical, genetic, and treatment data. STREAM’s dynamic design accommodates neglected populations, enabling comprehensive monitoring of outcomes while setting the foundation for ground-breaking clinical research.

“The success of IMPACT-AML will not be measured solely by the data collected, but by the ability of an entire community to act together, across different European nationalities,” concluded Martinelli. “IMPACT-AML, thanks also to the STREAM platform, should lead us toward a new therapeutic standard.”